A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects

• Drug: PF-06263726
  Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
• Drug: PF-06263726
  Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
• Drug: PF-06263726
  Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
• Drug: Placebo
  Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
• Drug: PF-06263726
  Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
• Drug: Placebo
  Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.

• Experimental: Cohort 1 Experimental Arm
  Intervention: Drug: PF-06263726
• Experimental: Cohort 2 Experimental Arm
  Intervention: Drug: PF-06263726
• Experimental: Cohort 3 Experimental Arm
  Intervention: Drug: PF-06263726
• Placebo Comparator: Cohort 3 Placebo Arm
  Intervention: Drug: Placebo
• Experimental: Cohort 4 Experimental Arm
  Intervention: Drug: PF-06263726
• Placebo Comparator: Cohort 4 Placebo Arm
  Intervention: Drug: Placebo

Inclusion Criteria:

• Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests.
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• Subjects willing to avoid tanning beds and sun exposure of the back during the study.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of application).
• Subjects with any active skin condition at the application site possibly affecting drug absorption (e.g. rash, sun burn, scars, tattoos).
• Subjects with a Draize score >0 of the test area (back) immediately prior to first treatment application.
• Subjects using topical prescription or nonprescription drugs/over the counter preparations on the back within 14 days of the first treatment application.
• Subjects not willing to avoid application of treatmentssuch as lotions or creams to the back throughout the study until follow-up.